183 related articles for article (PubMed ID: 32243215)
1. Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.
Utsunomiya A; Hasegawa M; Oyama N; Asano Y; Endo H; Fujimoto M; Goto D; Ishikawa O; Kawaguchi Y; Kuwana M; Ogawa F; Takahashi H; Tanaka S; Sato S; Takehara K; Ihn H
Mod Rheumatol; 2021 Jan; 31(1):162-170. PubMed ID: 32243215
[TBL] [Abstract][Full Text] [Related]
2. High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome.
Wannarong T; Muangchan C
Rheumatol Int; 2018 Dec; 38(12):2279-2288. PubMed ID: 30206672
[TBL] [Abstract][Full Text] [Related]
3. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
[TBL] [Abstract][Full Text] [Related]
4. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Lescoat A; Huang S; Carreira PE; Siegert E; de Vries-Bouwstra J; Distler JHW; Smith V; Del Galdo F; Anic B; Damjanov N; Rednic S; Ribi C; Bancel DF; Hoffmann-Vold AM; Gabrielli A; Distler O; Khanna D; Allanore Y;
JAMA Dermatol; 2023 Aug; 159(8):837-847. PubMed ID: 37378994
[TBL] [Abstract][Full Text] [Related]
7. Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study.
Peytrignet S; Manning J; Wragg E; Moore T; Samaranayaka M; Dinsdale G; Herrick AL
Scand J Rheumatol; 2019 May; 48(3):230-234. PubMed ID: 30394164
[TBL] [Abstract][Full Text] [Related]
8. Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicentre prospective observational study.
Hasegawa M; Asano Y; Endo H; Fujimoto M; Goto D; Ihn H; Inoue K; Ishikawa O; Kawaguchi Y; Kuwana M; Muro Y; Ogawa F; Sasaki T; Takahashi H; Tanaka S; Takehara K; Sato S
Rheumatology (Oxford); 2012 Jan; 51(1):129-33. PubMed ID: 22072085
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort.
Jaafar S; Lescoat A; Huang S; Gordon J; Hinchcliff M; Shah AA; Assassi S; Domsic R; Bernstein EJ; Steen V; Elliott S; Hant F; Castelino FV; Shanmugam VK; Correia C; Varga J; Nagaraja V; Roofeh D; Frech T; Khanna D
Arthritis Res Ther; 2021 Jun; 23(1):170. PubMed ID: 34127049
[TBL] [Abstract][Full Text] [Related]
10. Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis.
Mendoza FA; Lee-Ching C; Jimenez SA
Semin Arthritis Rheum; 2020 Feb; 50(1):135-139. PubMed ID: 31311679
[TBL] [Abstract][Full Text] [Related]
11. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database.
Frantz C; Huscher D; Avouac J; Hachulla E; Balbir-Gurman A; Riemekasten G; Siegert E; Lazzaroni MG; Carreira PE; Vettori S; Zanatta E; Ullman S; Czirjàk L; Kowal-Bielecka O; Distler O; Matucci-Cerinic M; Allanore Y;
Autoimmun Rev; 2020 Feb; 19(2):102452. PubMed ID: 31838157
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of endothelial vasodilatory function evaluated by EndoPAT in patients with systemic sclerosis.
Aozasa N; Hatano M; Saigusa R; Nakamura K; Takahashi T; Toyama T; Sumida H; Tamaki Z; Maki H; Minatsuki S; Komuro I; Sato S; Asano Y
J Dermatol; 2020 Jun; 47(6):609-614. PubMed ID: 32232898
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
15. Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan.
Kuwana M; Hasegawa M; Fukue R; Shirai Y; Ishikawa O; Endo H; Ogawa F; Goto D; Kawaguchi Y; Sato S; Ihn H; Takehara K
Mod Rheumatol; 2021 Mar; 31(2):386-393. PubMed ID: 32552202
[TBL] [Abstract][Full Text] [Related]
16. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.
Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V
Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and predictors of hand involvement in Thai patients with systemic sclerosis.
Wangkaew S; Sivasomboon C; Leungwatthananon W; Kasitanon N; Louthrenoo W
Int J Rheum Dis; 2018 Jan; 21(1):240-248. PubMed ID: 27456855
[TBL] [Abstract][Full Text] [Related]
18. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
19. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
